Somatostatin Inhibits prolactin secretion in the estradiol primed male rat

Publisher Website
Google Scholar
Abstract
The role of somatostatin in prolactin (PRL) secretion has not been clearly demonstrated. The effects of somatostatin on rat PRL secretion was examined in several different circumstances where the circulating PRL level is elevated: the estradiol primed intact male rat, normal and estradiol primed rats pretreated with pimozide, normal and estradiol primed hypophysectomized male rats with adenohypophyses grafted under the kidney capsule (HAG rat). Blood samples (70 .mu.l) were taken every 2 min via an indwelling atrial cannula from conscious, unrestrained animals. In the estradiol primed intact rats, a bolus injection of somatostatin (10, 100 and 1000 .mu.g/kg) lowered PRL levels in a dose-dependent manner. When the PRL concentration was elevated by the administration of pimozide (3 mg/kg), a dopaminergic receptor blocking agent, somatostatin was ineffective in decreasing plasma PRL concentration but the PRL concentration was lowered by somatostatin when the rat had been primed with estradiol. Somatostatin had no effect on the normal HAG rats, but lowered the plasma PRL concentration in the estradiol primed HAG rats. Since somatostatin inhibits PRL secretion only in the estradiol primed rats, it is suggested that estradiol priming creates a new environment, presumably via new or altered receptors, which can be inhibited by somatostatin.